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Abstract
Background: Breast cancer is the most common cancer in women, representing 16% of all female cancers.
According to the American Cancer Society, long-term cancer survival is defined as more than five years of
survivorship since diagnosis, with approximately 2.5 million breast cancer survivors (BCS) in 2006. The long-term
effects from breast cancer and its treatment have been shown to have positive and negative effects on both
recovery and survivors’ quality of life (QoL). The purpose of the study was to identify QoL instruments that have
been validated in long-term BCS and to review the studies that have used the QoL instruments in this population.
Methods: A systematic literature search was conducted from January 1990 to October 2010 using electronic
databases. Instruments validated and used in BCS were included in the review. In addition, QoL studies in long-
term BCS using the validated instruments were reviewed. The search was limited to studies in English language.
Studies of BCS of less than five years after initial diagnosis, any clinical or review studies were excluded.
Results: The review identified a total of 12 instruments (10 disease-specific, 2 condition-specific) validated in long-
term BCS. According to the QoL framework proposed by Ferrell and colleagues, three instruments (Quality of Life-
Cancer Survivors, Quality of Life in Adult Cancer Survivors Scale, and Quality of Life Index-Cancer Version) evaluated
all four domains (physical, psychological, social, and spiritual) of QoL. A review of the psychometric evaluation
showed that Quality of Life in Adult Cancer Survivors Scale has acceptable reliability, validity, and responsiveness in
long-term BCS compared to other disease-specific instruments. The review also yielded 19 studies that used these
QoL instruments. The study results indicated that age-group, ethnicity, and type of treatment influenced different
aspects of QoL.
Conclusions: There is a significant impact of breast cancer on QoL in long-term BCS. The review can help
researchers and clinicians select the most appropriate instruments to assess the changes in QoL in BCS.
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Introduction
Breast cancer is the most common cancer in women,
representing 16% of all female cancers [1]. Approxi-
mately 200,000 new cases of breast cancer are diagnosed
each year in the United States (US) [2]. Most significant
risk factors for the disease include age, gender, and
race/ethnicity [3]. Breast cancer incidence and death
rates generally increase with age; women older than 45
years are at the greatest risk [3]. In developed countries,
there has been a significant decline in the mortality rate
due to improved diagnosis and treatment programs. The
National Cancer Institute estimated approximately 2.5
million breast cancer survivors (BCS) in the US in 2006
[4].
The long-term effects from breast cancer and its treat-
ment have been shown to have positive and negative
effects on both recovery and survivors’ quality of life
(QoL). Also, QoL outcomes vary across the breast can-
cer continuum including diagnosis at different stages of
breast cancer, disease-free survivorship beyond the first
course of primary treatment, long-term disease-free sur-
vivorship, and first recurrence of breast cancer [5].
According to the American Cancer Society (ACS), a
long-term cancer survivor is defined as an individual
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of cancer [6]. Long-term difficulties resulting from
breast cancer differ from those experienced during diag-
nosis and treatment. Breast cancer patients are at an
increased risk of developing physical conditions (e.g.,
fatigue, sleep disturbances, and pain) and psychological
distress (e.g., depression, anxiety, negative thoughts, fear
of cancer recurrence and death, sense of aloneness, sex-
ual, and body image problems) after diagnoses that
adversely affect their overall QoL and survivorship [7].
The implementation and use of improved diagnosis
and treatment programs have resulted in decreased
breast cancer mortality [8]. However, these new long-
term therapies have persistent unknown side-effects and
toxicity, which have negatively impacted survivor’sQ o L
[8]. Different therapies including surgery, systemic
therapies (chemotherapy, hormone therapy, radiation
therapy, and newer targeted therapies with monoclonal
antibodies), and adjuvant endocrine therapy have varied
QoL outcomes [8]. Breast cancer surgery is associated
with lasting effects including pain, fatigue, and psycho-
social distress. The treatments involve the use of more
toxic and multimodal regimens with little focus on
long-term effects of therapies. Fatigue, weight gain, lym-
phedema, pain, and menopausal symptoms are long-
term effects that result from systemic therapies. The use
of anthracyclines and adjuvant trastuzumab have been
linked to the risk of developing cardiac problems even
after the treatment has ended, whereas women on aro-
matase inhibitors are at an increased risk of bone loss
and fractures [9]. The radiation therapy is linked to the
potential development of sarcomas [9]. It has been
reported that lack of knowledge in recovery patterns
and evidence-based guidelines for follow-up care mostly
result in persistent and late effects of cancer treatment
[7].
The problems resulting from breast cancer and its
treatment are varied and complex. Ferrell et al [10] pro-
posed a QoL model for long-term cancer survivors [7]
(Figure 1) that comprises of four primary domains of
well-being (psychological, social, physical, and spiritual)
that are integrally related and relevant to BCS. Thus, for
a better understanding of the long-term impact of can-
cer diagnosis and its treatment, it is important to exam-
ine all the four domains of a survivor’sw e l l - b e i n g .I n
addition, the health perceptions and expectations have
been found to vary with person’s age, experiences, gen-
der, and health history [11]. This further necessitates
the recognition of specific medical and psychosocial
needs so as to optimize health promotion in survivors.
Objectives
The specific objectives of this review were: (1) to iden-
tify QoL instruments validated and used in long-term
BCS; (2) to provide a description of the instruments and
their psychometric properties (reliability, validity, and
responsiveness) in long-term BCS; and (3) to provide a
systematic review of studies that used the QoL instru-
ments in long-term BCS.
Methods
Search strategy
Following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [12], a
systematic literature search was conducted among peer-
reviewed journals from January 1990 to October 2010
by the first author in electronic databases such as
Pubmed, PsychInfo, Embase, Cinahl, and Cochrane
review (Figure 2). For the purpose of the review, long-
term breast cancer survivor was defined as an individual
who had survived five or more years since the diagnosis
of cancer [6]. The search strategy included the following
keywords or their combinations: quality of life, health-
related quality of life, measures, scales, questionnaires,
breast cancer, breast carcinoma, breast cancer survivors,
long-term breast cancer survivors, post-treatment, post-
chemotherapy, post-radiation therapy,a n dpost-surgery.
The search was conducted to identify studies reporting
the use of QoL instruments in the evaluation of breast
cancer and its treatment in long-term BCS. The QoL
instruments used in these studies were also identified.
T h e s eQ o Li n s t r u m e n t sw e r et h e nr e v i e w e df o rt h e i r
validation in long-term BCS. The literature search pro-
cess is illustrated in Figure 2.
Inclusion and exclusion criteria
Instruments were included in the review if they were
used in at least one long-term BCS study and their
description and psychometric properties were reported
in BCS population with a varying number of survivor
years. All included instruments were identified as
patient-reported outcome questionnaires measuring one
or more aspects of QoL (physical, psychological, social,
and spiritual). The instruments that measured patient
satisfaction or patient preference were excluded. Also,
the instruments without any description of their devel-
opment or validation were excluded from the review.
In addition to the inclusion of instruments, the review
also included studies in long-term BCS that used these
validated instruments. The search was limited to studies
in English language and the use of the English version
of the QoL instrument. The ACS’s definition of long-
term survival (> 5 years since diagnosis) was used [6];
studies of BCS of less than five years after initial diagno-
sis were excluded. Some studies reporting QoL out-
comes for survivors with a varying number of years after
diagnosis were included only if a measure of time post-
diagnosis/treatment was included, the mean post-
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were presented separately for long-term survivors. Ran-
domized clinical studies focusing on breast cancer treat-
ments and review studies evaluating QoL in BCS were
excluded. Also excluded from the review were confer-
ence abstracts, dissertations, commentaries, editorials, or
summary reports on QoL. The inclusion of articles was
limited to BCS; studies on cancer survivors in general
were excluded.
Data extraction
There are generally three types of QoL instruments:
generic, disease-specific, and condition-specific. The
generic instruments are designed to measure the com-
plete spectrum of disease in various populations and are
useful in comparing QoL changes across different dis-
eases [13]. The disease-specific instruments assist in the
measurement of domains of QoL specific to a particular
disease. The condition-specific instruments measure
change in specific conditions related to a disease, such
as fatigue [13]. In addition to identifying the type of
QoL instrument, information on items, domains,
domain description, scaling and scoring, and administra-
tion of each QoL instruments was extracted.
The information on psychometric properties of the
instrument (reliability, validity, and responsiveness) was
also extracted. The QoL instruments are generally tested
for two types of reliability: internal consistency reliability
and test-retest reliability. The internal consistency relia-
bility is measured as Cronbach’sa l p h a( a) whereas the
test-retest reliability is estimated as Pearson product-
moment correlation coefficient (r). The validity refers to
the degree to which an instrument measures the con-
cept it is intended to measure. The responsiveness is the
ability to detect change in health status over time [13].
For the studies reporting the use of QoL instruments,
the following information was collected: sample size,
socio-demographic variables (age, ethnicity, employment
status, education, and number of years since diagnosis),
medical variables (type of treatment and tumor stage at
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Overall physical health 
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Pain/Aches 
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Figure 1 Specific quality of life model for breast cancer survivors. Adapted with permission from Betty Ferrell & Marcia Grant: Quality of Life
Conceptual Model Applied to Cancer Survivors, City of Hope Beckman Research Institute [10].
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tion of population for their studies, QoL instruments
used, administration of QoL instrument, and survivor’s
QoL.
Results
Validated QoL measures in long-term BCS
A total of 12 QoL instruments (10 disease-specific and
two condition-specific) were identified and included in
the review [14-27]. The disease-specific instruments
were further categorized into cancer-specific and breast
cancer-specific instruments. The cancer-specific instru-
ments included Functional Assessment of Chronic Ill-
ness Therapy-Spiritual Well Being Scale (FACIT-SP),
Quality of Life-Cancer Survivor (QOL-CS), Ferrans and
Powers’s Quality of Life Index-Cancer Version (QLI-
CV), Quality of Life in Adult Cancer Survivors Scale
(QLACS), Cancer Rehabilitation Evaluation System Can-
cer-Short Form (CARES-SF), European Organization for
Research and Treatment of Cancer (EORTC QLQ-C30),
764 articles identified 
through database search 
(Pubmed, PsychInfo, 
Embase, Cinahl, Cochrane) 
161 full text articles were 
reviewed 
Articles excluded 
  85 studies of BCS (< 5 years since initial diagnosis) 
  10 studies used non-English version of questionnaire 
24 were review studies
42 studies screened for 
different QoL instruments 
used in long-term BCS (> 5 
years since diagnosis) 
12 QoL instruments validated 
in long-term BCS included  
Using these 12 QoL instruments, 
19 studies reporting the use of 
these instruments were included  
58 QoL instruments (from 42 
studies screened) were reviewed for 
their validation in long-term BCS  
QoL instruments excluded 
46 instruments were validated in 
general population 
Articles excluded 
  256 duplicate articles 
  290 studies not relevant to topic 
  57 studies were on cancer survivors 
764 articles identified 
through database search 
(Pubmed, PsychInfo, 
Embase, Cinahl, Cochrane) 
161 full text articles were 
reviewed 
42 studies screened for 
different QoL instruments 
used in long-term BCS (> 5 
years since diagnosis) 
Figure 2 Schematic presentation of methodology used and selection criteria. Search and selection criteria conducted in accordance with
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement criteria [12].
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(FACT-G), and Body Image and Relationships Scale
(BIRS). The breast cancer-specific instruments mostly
used along with cancer-specific instruments included
European Organization for Research and Treatment of
Cancer-Breast Module (EORTC QLQ-BR23) and Func-
tional Assessment of Cancer Therapy-Breast (FACT-B).
Fatigue Symptom Inventory (FSI) and Multidimensional
Fatigue Symptom Inventory (MFSI) were the two condi-
tion-specific instruments validated in long-term BCS
and were included in the review.
Description of the instruments and their psychometric
properties
The instruments varied widely in number of items and
domains, mode of administration, scaling and scoring,
and psychometric properties. The different measures
used in BCS and their complete description such as
items, domains, scaling, scoring, and means of adminis-
tration is provided in Table 1. The number of items and
domains in the instruments ranged from 12-83 and 2-
12, respectively. According to the QoL framework pro-
posed by Ferrell et al., three of the identified disease-
specific instruments (QOL-CS, QLACS, and QLI-CV)
evaluated all four domains (physical, psychological,
social, and spiritual) of QoL and included items consis-
tent with survivor’s concerns [20,24,25]. Other disease-
specific instruments (EORTC QLQ-C30, EORTC QLQ-
BR23, FACT-G, FACT-B, CARES-SF, and BIRS)
included both physical and psychosocial domains
[14-19,21,22], while FACIT-SP assessed only the spiri-
tual aspect of QoL [23]. There are only two condition-
specific instruments (FSI and MFSI) validated in BCS
and both measure fatigue [26,27]. In terms of adminis-
tration, most of the instruments such as EORTC QLQ-
C30, EORTC QLQ-BR23, FACIT-SP, QOL-CS, QLI-CV,
and MFSI could be self-administered or administered by
an interviewer. The administration time for some instru-
ments, such as EORTC QLQ-C30, FACT-G, FACT-B,
and MFSI, was reported to range from 5 to 15 minutes.
The psychometric properties of the instruments used
in BCS are presented in Table 2. All the QoL instru-
ments reviewed in the study reported an overall internal
consistency reliability (a) in the range of 0.70-0.98.
Additionally, QLACS reported a for specific domains:
generic (a = 0.95) and cancer-specific (a =0 . 9 8 ) .Q O L -
CS, FACT-G, and FACT-B also reported test-retest
reliability which ranged from 0.85 to 0.92. The instru-
m e n t sw e r ea l s ot e s t e df o ro n eo rm o r ev a l i d i t ym e a -
sures with criterion-related and construct validity being
the most commonly used validity measures. Besides
reliability and validity, responsiveness was reported for
QLACS, EORTC QLQ-BR23, FACT-B, and MFSI. An
overall psychometric review of the instruments reveal
that QLACS has a high internal consistency reliability,
validity, and responsiveness compared to other instru-
ments in BCS. The generic measures have not been vali-
dated in breast cancer population and were not included
in this review.
Review of studies using validated QoL measures in long-
term BCS
Based on the literature search methodology, 19 studies
were identified that reported the use of QoL instru-
ments in long-term BCS [28-46]. Table 3 provides a
summary of the studies including information regarding
sample size, survivor’s age, number of years of post-
diagnosis, inclusion/exclusion criteria of the study, survi-
vorship, QoL instruments used, administration of QoL
instrument, and survivor’s QoL.
Most of the studies utilized two or more QoL instru-
ments to assess different aspects of QoL in long-term
BCS. Cancer-specific QoL instruments designed to mea-
sure physical and psychosocial domains were used by
six studies [28,30,31,34,36,46], while the cancer-specific
QoL instruments (QOL-CS, QLACS, QLI-CV) that mea-
sured all four aspects of QoL were used by nine studies
[28,29,33,35,37,38,40,43,44]. The breast cancer-specific
measures designed to evaluate physical and psychosocial
aspects specific to breast cancer were used by five stu-
dies [31,32,38,41,45]. Two studies have used FACIT-SP,
an instrument for measuring spiritual aspect of QoL
[39,42]. Condition-specific instruments were used by
two studies to measure fatigue in BCS [39,42].
The results from the 19 studies are summarized into
six categories, although some studies met the criteria for
more than one category. These include overall QoL and
effect of different demographic and medical variables
(life stage, old age, ethnicity, breast cancer treatment,
and non-pharmacological intervention) on QoL.
Overall QoL
Five studies assessed the effect of breast cancer and its
treatment on overall QoL among long-term BCS
[28,29,34,39,40]. The results of the study by Dow et al.
[28] indicated both positive and negative long-term
effects. The positive outcomes included hopefulness and
presence of positive change after treatment. The major
concerns included fatigue, aches and pains, sleep pro-
blems, psychological distress from cancer diagnosis and
treatment, fear of recurrence, family distress, sexuality,
family burden, and uncertainty which had negative
impact on overall QoL. Helgeson et al. [39] indicated
difficulties in physical functioning in disease-free BCS.
Additionally, the survivors with recurrence had poor
QoL compared to the survivors without recurrence.
Weitzner et al. [29] assessed overall QoL as well as rela-
tionship between mood and QoL. They compared long-
term BCS with women in breast cancer screening group.
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Instruments Domains
(Items)
Domain description Ferrell’s QoL
domains *
Scaling & scoring/Administration
Ph. Ps. So. Sp.
Disease-specific measures
Body Image and
Relationships Scale (BIRS)
[14]
3 (32) Strength and health; Social barriers;
Appearance and sexuality
✓✓✓ 5-point Likert scale; 1 (Strongly disagree)
to 5 (strongly agree).
Total and subscale score = summing all
item scores. Higher score indicates
greater impairment.
Self-administered
Cancer Rehabilitation
Evaluation System Cancer-
Short Form (CARES-SF) [15]
6 (59) Global CARES-SF; Physical; Psychosocial;
Medical interaction; Marital relationship;
Sexual concerns
✓✓✓ 5-point scale ranging from 0 ("not at all";
no problem) to 4 ("very much"; severe).
Higher scores represent poorer QoL.
Self-administered
European Organization for
Research and Treatment of
Cancer (EORTC QLQ-C30)
[16-18]
10 (30) Functional domains: Physical; Role;
Emotional; Cognitive; Social; Global QoL
Symptom domains: Fatigue; Nausea/
vomiting; Pain
Single-item domain: Dyspnea, appetite
loss, sleep disturbance, constipation,
diarrhoea
✓✓✓ Physical and role function, dichotomous
(Yes/No); Global QoL, 7-point scale; Other
items, 4-point Likert scale ranging from 1
(not at all) to 4 (very much).
Scale scores = mean of item scores,
rescaled to 0 to 100, with higher function
subscale scores indicating less
dysfunction and higher symptom
subscale scores indicating more
dysfunction.
Self-administered, interviewer-
administered.
Time to administer: 15 min.
European Organization for
Research and Treatment of
Cancer-Breast Module
(EORTC QLQ-BR23) [19]
8 (23) Body image; Sexual functioning; Arm
symptoms; Breast symptoms; Sexual
enjoyment; Systemic therapy side-effects;
Future perspective; Upset by hair loss
✓ 4-point scale ranging from 1 (not at all)
to 4 (very much).
Scale scores = mean of item scores,
rescaled to 0 to 100.
Self-administered, interviewer-
administered
Ferrans and Powers’s Quality
of Life Index-Cancer Version
(QLI-CV) [20]
2 (70) Satisfaction with various domains of life
(Part 1): Health and functioning;
Socioeconomic; Psychological/spiritual;
Family
Importance of the same domains to the
subject (Part 2): Health and functioning;
Socioeconomic; Psychological/spiritual;
Family
✓✓✓✓6-point Likert-type scale ranging from 1
(very dissatisfied) to 6 (very satisfied) for
PART 1, and 1 (very unimportant) to 6
(very important) for PART 2.
Overall & Subscale scores range from 0 to
30.
Higher scores indicate better QoL.
Self-administered, interviewer-
administered
Functional Assessment of
Cancer Therapy-Breast
(FACT-B) [21]
7 (44) Emotional well-being; Functional well-
being; Physical well-being; Social/family
well-being; Relationship with doctor;
Breast cancer subscale; Additional
concerns
✓✓✓ 5-point Likert scale; 0 (not at all) to 4
(very much).
Total FACT-B score has a range of 0 to
144.
Self-administered. Time to administer: 10
min.
Functional Assessment of
Cancer Therapy-General
(FACT-G) [22]
5 (28) Emotional well-being; Functional well-
being; Physical well-being; Social/family
well-being; Relationship with doctor
✓✓✓ 5-point Likert scale; 0 (not at all) to 4
(very much).
Item scores are summed to form overall
and subscale scores.
Higher scores indicate less dysfunction.
Self-administered. Time to administer: 5
min.
Functional Assessment of
Chronic Illness Therapy-
Spiritual Well Being Scale
(FACIT-SP) [23]
2 (12) Faith; Purpose ✓ 5-point scale ranging from 0 (not at all)
to 4 (very much).
Higher scores indicate stronger spiritual
beliefs.
Self-administered, interviewer-
administered
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symptoms related to depression and trait anxiety, result-
ing in lower QoL. The patients with advanced stage of
cancer had poorer QoL. Kornblith et al. [34] reported
that majority of the BCS presented a significant recovery
from their cancer diagnosis and treatment, but some
survivors reported cancer-related emotional and medical
problems due to lymphedema and numbness in hands
and feet that interfered with their QoL. Carver et al.
[40] investigated the effect of medical, demographic, and
psychosocial variables on different aspects of QoL. The
study showed that medical variables such as stage of dis-
e a s ea n dt r e a t m e n ti n t e n s i t yw e r es t r o n g l ya s s o c i a t e d
with financial problems and worries about appearance.
The psychosocial variables, such as earlier trait opti-
mism, confidence about remaining cancer free, and per-
ceptions of available social support predicted variations
in psychosocial aspects of QoL. The demographic vari-
ables including older age at cancer diagnosis, more time
elapsed since diagnosis, being non-Hispanic white, being
more educated, and having employment predicted lower
psychosocial distress.
Life stage and QoL
Three studies examined the relationship between life
stage variables (survivor’s age at diagnosis and number
of years of post-diagnosis survivorship) and QoL
[31,33,36]. Cimprich et al. [33] categorized their sample
into three groups based on their age at diagnosis:
younger age (27-44 years), middle-aged (45-65 years),
and older age (> 65 years). The younger-age at diagnosis
group showed poorer outcomes in social aspect, with
major concerns being changes in self-concept and
appearance. The group of patients who had received
diagnosis at an older age had the worst QoL in relation
to physical well-being, with major problems being fati-
gue, pains, sleep changes, and constipation. There were
differences in the psychological aspect also. The con-
cerns of older-age at diagnosis group included feeling
less useful in life and uncertainty about the future. The
younger-age group at diagnosis showed psychological
distress related to family distress, diagnosis, and treat-
ment. Interestingly, the QoL improved with an increase
in the number of post-diagnosis years. Casso et al. [36]
used a sample of BCS who were diagnosed between the
ages of 40-49 years. Their findings suggested a varied
response to QoL depending on the type of breast cancer
treatment received. Women who received adjuvant sys-
temic therapy had poorer QoL outcomes in physical,
psychosocial, and sexual aspects compared to women
who did not receive adjuvant systemic therapy. Similarly,
Table 1 Description of quality of life instruments in long-term breast cancer survivors. (Continued)
Quality of life-Cancer
Survivor (QOL-CS) [24]
4 (41) Physical well-being; Psychological well-
being; Social well-being; Spiritual well-
being
✓✓✓✓Visual analog scale ranging from 0 (worst)
to 1 (best).
Average of Scores (Overall & Subscale
scores range from 0 to 1). Higher scores
indicate better QoL.
Self-administered, interviewer-
administered
Quality of Life in Adult
Cancer Survivors Scale
(QLACS) [25]
12 (47) Generic domains: Physical pain; Negative
feelings; Positive feelings; Cognitive
problems; Sexual problems; Social
avoidance; Fatigue
Cancer-specific domains: Distress about
family; Distress about recurrence;
Appearance concerns; Benefits of cancer;
Financial problems resulting from cancer
✓✓✓✓Each item score range from 1 (Never) to
7 (Always).
Scores for each domain are the sum
(after appropriate reverse scoring) of the
individual item scores.
Domain scores range from 4-28 points.
Higher scores represent poorer QoL.
Self-administered
Condition-specific measures
Fatigue Symptom Inventory
(FSI) [26]
3 (13) Intensity of fatigue; Interference of fatigue;
Fatigue duration
✓ Visual analog scale, 0 to 10.
Intensity of fatigue (0 = not at all fatigued
and 10 = extreme fatigue); Interference of
fatigue (0 = no interference and 10 =
extreme interference); Fatigue duration (0
= none of the day and 10 = the entire
day).
Scores range from 0-96. Higher scores
indicating greater impact of fatigue.
Self-administered
Multidimensional Fatigue
Symptom Inventory (MFSI)
[27]
5 (83) Global fatigue; Somatic symptoms;
Affective symptoms; Behavioral symptoms;
Cognitive symptoms
✓ 5-point scale ranging from 0 (not at all)
to 4 (extremely).
Self-administered, interviewer-
administered
Time to administer: 5-10 min.
* Ph. = Physical; Ps. = Psychological; So. = Social; Sp. = Spiritual
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concerns compared to women who had breast conser-
ving therapy. Moreover, the presence of breast-related
symptoms such as pain, swelling, and numbness resulted
in poor QoL. These concerns, however, were not
affected by the number of years post-diagnosis. The
s t u d yb yH o l z n e ret al. [31] focused on the effect of
time elapsed since initial diagnosis on QoL. The reduced
QoL was observed not only in patients in the first two
years after initial treatment but also in patients with a
survival time of more than 5 years. The authors
observed a “rebound effect” (a recurring reduction of
QoL after initial improvement) in their study, particu-
larly in the psychosocial aspect of QoL. It was suggested
that the long-term BCS’s concerns arose with the neces-
sity for regular aftercare visits, chronic physical long-
term effects of cancer treatment (arm swelling or scar
pain), and fear of possible recurrence which makes the
survivors continually aware of the illness they have sur-
vived. A similar pattern was observed for the aspect of
role functioning, where patients reported the difficulties
in occupational tasks, organizing leisure time activities,
and pursuing their hobbies.
Age of breast cancer survivor and QoL
Two studies examined the effect of different age groups
on QoL [35,42]. Sammarco et al. [35] assessed QoL in
BCS older than 50 years of age. A significant association
was observed between perceived social support and the
physical aspects of QoL. The findings suggested that the
unpredictable nature of breast cancer and its treatment
coupled with the presence of other diseases or func-
tional disabilities of aging resulted in poorer QoL, espe-
cially in the health/functioning, socioeconomic, and
psychological/spiritual domains. Moreover, fear of
Table 2 Psychometric properties of quality of life instruments in long-term breast cancer survivors.
Instruments Reliability Validity Responsiveness
Disease-specific measures
Body Image and Relationships
Scale (BIRS) [14]
Internal consistency = 0.94 Convergent and
divergent
Not Reported
Cancer Rehabilitation Evaluation
System Cancer-Short Form (CARES-
SF) [15]
Internal consistency (for domains,
0.85-0.61)
Concurrent Not Reported
European Organization for
Research and Treatment of Cancer
(EORTC QLQ-C30) [16-18]
Internal consistency > 0.70 Content, concurrent,
discriminant
Not Reported
European Organization for
Research and Treatment of Cancer-
Breast Module (EORTC QLQ-BR23)
[19]
Internal consistency: American
sample (0.70-0.91); Dutch sample
(0.57-0.89); Spanish sample (0.46-
0.94)
Content, construct,
criterion-related
Dutch &Spanish sample showed responsiveness
in side effects & body image; no responsiveness
tested in American sample.
Ferrans and Powers’s Quality of Life
Index-Cancer Version (QLI-CV) [20]
Internal consistency = 0.95 Concurrent (criterion-
related, r = 0.80),
construct.
Not Reported
Functional Assessment of Cancer
Therapy-Breast (FACT-B) [21]
Internal consistency = 0.90
Test-retest = 0.85
Content, construct,
concurrent (r = 0.87),
divergent, known
group
Sensitivity to 2-month changes found for FACT-
B global, FACT-G global, physical well-being,
functional well-being, breast cancer subscale.
Functional Assessment of Cancer
Therapy-General (FACT-G) [22]
Internal consistency = 0.89
Test-retest = 0.92
Content, construct,
divergent, known
group.
Not Reported
Functional Assessment of Chronic
Illness Therapy-Spiritual Well Being
Scale (FACIT-SP) [23]
Internal consistency = 0.81-0.88 Discriminant,
convergent
Not Reported
Quality of Life-Cancer Survivors
tool (QOL-CS) [24]
Internal consistency = 0.93
Test-retest = 0.89
Content, concurrent (r
= 0.78), predictive,
construct, discriminate
Not Reported
Quality of Life in Adult Cancer
Survivors Scale (QLACS) [25]
Internal consistency (generic = 0.95,
cancer-specific = 0.98)
Concurrent,
retrospective
Change in health status
Condition- specific measures
Fatigue Symptom Inventory (FSI)
[26]
Internal consistency > 0.70 Convergent, divergent,
construct
Not Reported
Multidimensional Fatigue Symptom
Inventory (MFSI) [27]
Internal consistency = 0.87-0.92 Convergent and
divergent
Significant differences in expected direction
were found between cancer patients and non-
cancer patients.
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Study Study objective Patient population Inclusion/exclusion
criteria
Instruments
used/
Administration
Results Ferrell’s
QoL
domains
*
Dow et al.
(1996) [28]
Evaluation of QoL
in long-term BCS.
N = 294; mean post-
cancer survivorship = 68.5
months; mean age = 50.9
years.
Not reported QOL-CS, FACT-G
Self-
administered
Concerns included
psychological/family
distress, fear of recurrence,
uncertainty, fatigue, chest
pain, sleep problems, and
sexuality.
Ph.
Ps.
So.
Sp.
Weitzner et
al. (1997)
[29]
Comparison of
mood and QoL of
BCS with those
observed in low-
risk breast cancer
screening patients.
Long-term stage I-III BCS
(N = 60); mean age = 53.8
years. Low-risk breast
cancer screening patients
(N = 93); mean age = 45.3
years. Mean post-cancer
survivorship ≥ 5 years.
Inclusion (BCS): disease-
free ≥ 5 years; stage I, II,
or III; age < 70 years.
Inclusion (comparison
group): no personal/family
history of breast cancer.
Exclusion (both groups):
DSM-III-R psychiatric
diagnosis; brain
carcinoma; using steroids/
narcotic analgesics.
QLI-CV; other
instruments (BDI,
STAI)
Self-
administered
Stage III breast cancer
resulted in significantly
poorer functioning
compared to other
groups.
Ps.
So.
Ashing-
Giwa et al.
(1998) [30]
Evaluation of QoL
of long- term BCS
and to examine
the role of
ethnicity.
African-American: N = 117;
mean post-cancer
survivorship = 6.5 years;
White respondents: N =
161); mean post-cancer
survivorship = 7.4 years.
Inclusion: breast
carcinoma diagnosis
between 1989 and 1990;
previously participated in
a study of first-degree
relatives of BCS by Bastani
et al.
CARES-SF; other
instruments (SF-
36, Ladder of
Life Scale, Life
Distress Scale).
Self-
administered
Overall, BCS reported
favorable health-related
QoL. Differences in QoL
outcomes were
attributable to
socioeconomic and life-
burden factors and not to
ethnicity.
Ph.
So.
Holzner et
al. (2001)
[31]
Evaluation of effect
of time elapsed
since initial
diagnosis on QoL.
N = 87; mean post-cancer
survivorship = 5.1 years;
mean current age = 53.9
years.
Inclusion: Relapse-free
patients.
Exclusion: presence of
other severe diseases.
EORTC QLQ-C30,
EORTC QLQ-
BR23, FACT-B.
Self-
administered
Emotional, social, and
sexual functioning areas
showed reduced QoL after
initial treatment (1-2 years)
and > 5 years survival.
Ps.
So.
Beaulac et
al. (2002)
[32]
Evaluation of effect
of surgical
treatment related
lymphedema on
QoL.
Women with
lymphedema, (N = 42),
without lymphedema (N =
109); mean post-cancer
survivorship = 5.0 years;
mean age = 62.4 years.
Inclusion: mastectomy or
breast-conserving surgery
with radiation; level I, II
axillary lymph node
dissection. Exclusion: other
breast surgery;
chemotherapy;
rheumatologic condition.
FACT-B. Self-
administered
Women with lymphedema
reported lower breast,
functional, and physical
wellbeing, irrespective of
type of surgery.
Ph.
Ps.
So.
Cimprich
et al.
(2002) [33]
Evaluate
relationship
between life-stage
variables on QoL in
BCS.
Diagnosis age: young (<
45 years, N = 42), middle
(45-65 years, N = 35), old
(> 65 years, N = 28); mean
post-cancer survivorship =
11.5 years.
Inclusion: at least 5 years
past the diagnosis; no
recurrent disease or other
cancer diagnosis.
QOL-CS
Self-
administered
Long-term BCS diagnosed
at an older age had worse
QoL in physical domain
and women diagnosed at
a younger age had worse
QoL in social domain.
Ph.
Ps.
So.
Kornblith
et al.
(2003) [34]
Assessing the long-
term impact of
breast carcinoma
in BCS.
Phase III randomized trial
CALGB 7581] group; N =
153; mean post-cancer
survivorship = 18 years;
age (range) = 41-87 years.
Inclusion: no evidence of
breast carcinoma;
completion of all cancer
treatment at least1 year
interview; no major
psychiatric/cognitive
deficit.
EORTC QLQ-C30;
other
instruments (BSI,
LES, OARS, PCL-
C). nterviewer-
administered
Persistent psychological
effects were observed in
BCS long after treatment
completion.
Ph.
Ps.
So.
Sammarco
et al.
(2003) [35]
Evaluation of
relation among
social support,
uncertainty, and
QoL in older BCS.
Older women (> 50 years);
N = 103; mean post-
cancer survivorship = 5.0
years; mean age = 68
years.
Inclusion: > 50 years; able
to read and respond in
English.
QLI-CV; other
instruments
(SSQ, MUIS-C).
Self-
administered
There was significant
association between
perceived social support
and QoL. Uncertainty
resulted in poorer QoL.
Ph.
Ps.
So.
Sp.
Casso et al.
(2004) [36]
Assessing QoL of
long-term BCS
diagnosed at age
of 40-49 years.
N = 216; mean post-
cancer survivorship = 7.3
years; age (range) = 45-60
years.
Inclusion: women with an
initial diagnosis of ductal
carcinoma in situ (DCIS) or
invasive breast cancer;
diagnosis age of 40-49
years.
CARES-SF; other
instruments (SF-
36, CES-D). Self-
administered
Long-term QoL affected
by surgery/chemotherapy/
hormonal therapy.
Negative impact of breast
related symptoms/pain on
QoL.
Ph.
So.
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Ahles et al.
(2005) [37]
Comparison of
local therapy and
standard-dose
systemic
chemotherapy on
BCS’s QoL.
Women treated with
standard-dose systemic
chemotherapy (N = 141,
mean age = 57 years) or
local therapy (N = 294,
mean age = 65.8 years);
mean post-cancer
survivorship = 10.0 years.
Inclusion: > 5 years after
diagnosis; currently
disease free; currently
receiving no cancer
treatments.
QOL-CS.
Interviewer-
administered
Survivors treated with
systemic chemotherapy
exhibited lower overall
QoL compared with
survivors treated with local
therapy only.
Ph.
Ps.
So.
Burckhardt
et al.
(2005) [38]
Evaluation of effect
of chronic pain on
health status and
overall QoL
resulting from
surgical treatment.
Women with regional
pain: N = 11; mean post-
cancer survivorship = 5.9
years; mean age = 58.7
years and with widespread
pain: N = 12; mean post-
cancer survivorship = 5.4
years; mean age = 56.8
years.
Inclusion: post-
mastectomy ≥ 6 months/
≥ 3 months post-
radiation/cytotoxic
chemotherapy; cancer-
free; simple mastectomy/
lumpectomy/modified
radical mastectomy.
Exclusion: breast surgery
for cosmetic reasons or
prophylactic mastectomy;
arthritis.
FACT-B, QOLS;
other
instruments (BPI,
MPQ-SF, FIQ, SF-
36). Self-
administered
Women who experienced
widespread pain after
breast cancer surgery had
significantly more severity
of pain and lower physical
health status than those
with regional pain.
Ph.
Ps.
So.
Helgeson
et al.
(2005) [39]
Examining the
impact of breast
cancer on long-
term QoL.
Survivors, N = 267, mean
age = 54.4 years. Controls,
N = 187, mean age = 53.2
years; mean post-cancer
survivorship = 5.5 years.
Inclusion: Women with
Stage I, II, or III breast
cancer who underwent
surgery followed by
adjuvant chemotherapy
between 1993 and 1996.
FACIT-SP, MFSI;
other
instruments (SF-
36, PANAS, BSI,
DAS, IES).
Interviewer-
administered
Survivors reported more
difficulties with physical
functioning and more
physical symptoms.
Ph.
So.
Carver et
al. (2006)
[40]
Assessing the
effect of medical,
demographic, and
personal variables
on BCS’s QoL.
N = 163; mean post-
cancer survivorship = 10.0
years; mean age at
diagnosis = 54.2 years.
Inclusion: Women who
participated in the past
projects (1988-1995, 1994-
1996).
QLACS; other
instruments
(LOT, ISEL). Self-
administered
Initial chemotherapy and
higher stage predicted
more financial problems
and worry about
appearance. More distress
and social avoidance in
Hispanic BCS.
Ph.
Ps.
So.
Dirksen et
al. (2007)
[41]
Evaluation of
efficacy of
cognitive
behavioral therapy
on fatigue, mood,
and QoL in BCS.
N = 86; mean post-cancer
survivorship, CBT group =
85.3 months & control =
63.8 months; mean age =
58 years.
Inclusion: stage I, II or III,
≥ 3 months post-
treatment; disease-free;
sleep problem ≥ 3
months. Exclusion:
cognitive impairment or
other sleep disorders
(restless leg syndrome).
FACT-B; other
instruments
(STAI, CES-D,
POMS). Self-
administered
Women receiving
cognitive behavioral
therapy for insomnia had
significant improvements
in fatigue, trait anxiety,
depression and QOL.
Ph.
Ps.
So.
Perkins et
al. (2007)
[42]
Evaluation of
individual
differences in well-
being in older BCS.
N = 127; mean post-
cancer survivorship = 5.1
years; mean age = 78.2
years.
Inclusion: BCS survivors
with a current age of 70
or older.
FACIT-SP, FSI;
other
instruments (SF-
36, LOT-R). Self-
administered
Higher age predicted
increased depression.
Poorer health status was
associated with poorer
well-being.
Ph.
Ps.
So.
Sp.
Leak et al.
(2008) [43]
Examining relation
among symptom
distress, spirituality,
and QoL of
African- American
BCS.
N = 30; mean post-cancer
survivorship = 5.6 years;
mean age 55.5 years.
Inclusion: speak and read
English; had diagnosis of
breast cancer; treatment
completion (Jan 1, 1980 -
June 1, 2004). Exclusion:
recurrent breast cancer/
another cancer in the past
12 months.
QLI-CV; other
instruments
(SDS, SPS).
Interviewer
-administered
Sleep disturbance, fatigue,
and pain were the most
commonly reported
symptoms in African-
American BCS.
Ph.
Ps.
So.
Sp.
Sammarco
et al.
(2008) [44]
Examining relation
among perceived
social support and
uncertainty on
Hispanic BCS’s QoL.
N = 89; mean post-cancer
survivorship = 5.0 years;
age (range) = 30-86 years.
Inclusion: at least one year
after treatment.
QLI-CV; other
instruments
(SSQ, MUIS-C).
Self-
administered
Perceived social support
and uncertainty play a
pivotal role in managing
or maintaining QoL in
Hispanic BCS.
Ph.
Ps.
So.
Sp.
Skrzypulec
et al.
(2008) [45]
Evaluate problems
related to total and
partial mastectomy
affecting QoL.
Treatment with total
mastectomy (N = 403,
mean age = 57.8 years);
partial mastectomy (N =
91, mean age = 47.3
years); post-cancer
survivorship = 6-10 years.
Inclusion: total
mastectomy due to breast
cancer (research group);
partial mastectomy
(control group). Exclusion:
using drugs impeding
sexual function.
EORTC QLQ-
BR23; other
instruments (IES,
LSI, HADS). Self-
administered
The level of depression
and anxiety in women
after mastectomy results
in worse bio-psychosocial
functioning.
Ph.
So.
Chopra and Kamal Health and Quality of Life Outcomes 2012, 10:14
http://www.hqlo.com/content/10/1/14
Page 10 of 15recurrence, fear of death and suffering, and concerns
regarding payment for the healthcare costs affected QoL
among older survivors. The increased uncertainty in ill-
ness negatively impacted their QoL. Perkin et al. [42]
evaluated QoL in survivors aged 70 years or older and
reported a significant association between health status
variables of physical functioning, life satisfaction, depres-
sion, and general health perceptions.
Ethnicity and QoL
Four studies evaluated the relationship between long-
term effects of breast cancer on QoL and ethnicity
[30,40,43,44]. Sammarco et al. [44] assessed the overall
QoL among Hispanic BCS. The findings showed that
perceived social support and uncertainty were important
in providing improved QoL in this population. The His-
panic survivors experienced a higher degree of uncer-
tainty and were not aware of the available social support
resources which affected their QoL. Their major con-
cerns included family distress, socioeconomic problems,
and problems with health and functioning. Another
study by Carver et al. [40] in the Hispanic population,
observed that Hispanic women reported elevations in
several kinds of problems: negative feelings, social avoid-
ance, distress about the family’s future, and distress
about the possibility of recurrence compared to all other
ethnic groups. Leak et al. [43] examined the overall
QoL among African-American BCS. Sleep disturbance,
pain, and fatigue were the most commonly reported
symptoms in this population. The overall high QoL
scores were attributed to the relatively high level of
spirituality, which helped them cope with cancer. Ash-
ing-Giwa et al. [30] also compared the overall QoL
among African-American BCS with Caucasian BCS and
reported an improved health status and fairly good over-
all QoL in both the groups. The differences in QoL
between the groups were not attributable to ethnicity;
i n s t e a dt h e yr e s u l t e df r o md ifferences in the socioeco-
nomic and life-burden factors.
Breast cancer treatment and QoL
Four studies evaluated the effect of breast cancer treat-
ment on different aspects of QoL or overall QoL
[32,37,38,45]. Beaulac et al. [32] examined the effect of
lymphedema on QoL resulting from surgical treatment.
The authors observed that lymphedema resulted in
decreased range of arm motion and women with lym-
phedema reported lower breast, functional, and physical
wellbeing. However, the lymphedema related problems
were not affected by the type of surgical treatment
(mastectomy or breast conserving surgery). Additionally,
Burckhardt et al. [38] focused on BCS with regional
pain and widespread pain resulting from surgical treat-
ment. Most of the patients experienced chronic pain
immediately after surgery or in the early post surgical
treatment period which had lingering effects. However,
the chronic pain also originated later in the post-surgical
period. Skrzypulec et al. [45] examined the effect of sur-
gical treatment focusing on total and partial mastect-
omy. Mastectomy resulted in physical limitations and
interfered with the psychological and social functioning
in these women, which in turn adversely affected every-
day QoL and lowered the long-term QoL. Ahles et al.
[37] focused on long-term BCS who were treated with
either standard dose systemic chemotherapy or local
therapy (treating a lesion or tumor). There was a signifi-
cant negative impact on the social and physical aspects
of QoL in survivors treated with chemotherapy
Table 3 Quality of life studies in long-term breast cancer survivors. (Continued)
Speck et al.
(2010) [46]
Evaluation of
impact of Physical
Activity and
Lymphedema (PAL)
trial on perceptions
of body image in
BCS.
BCS with lymphedema (N
= 112); without
lymphedema (N = 122).
Post-cancer survivorship >
5 years.
Inclusion: unilateral non-
metastatic breast cancer;
BMI < 50 kg/m
2; cancer-
free; no medical
conditions limiting
participation in exercise
program; no weight lifting
in year prior to study
entry, not currently
pregnant/lactating.
BIRS
Self-
administered
Twice-weekly strength
training positively
impacted self-perceptions
of appearance, health,
physical strength,
sexuality, relationships,
and social functioning.
Ph.
So.
* Ph. = Physical; Ps. = Psychological; So. = Social; Sp. = Spiritual
Other instruments: instruments validated in general population and used in the included studies.
BDI = Beck Depression Inventory; BIRS = Body Image and Relationships Scale; BPI = Brief Pain Inventory; BSI = Brief Symptom Inventory; CALGB = Cancer and
Leukemia Group B; CARES-SF = Cancer Rehabilitation Evaluation System Cancer-Short Form; CBT = Cognitive Behavioral Therapy; CES-D = Center for
Epidemiologic Studies Depression Scale; DAS = Dyadic Adjustment Scale; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer; EORTC
QLQ-BR23 = European Organization for Research and Treatment of Cancer-Breast Module; FACT-B = Functional Assessment of Cancer Therapy-Breast; FACT-G =
Functional Assessment of Cancer Therapy-General; FACIT-SP = Functional Assessment of Chronic Illness Therapy-Spiritual Well Bring Scale; FIQ = Fibromyalgia
Impact Questionnaire; FSI = Fatigue Symptom Inventory; HADS = Hospital Anxiety and Depression Scale; IES = Impact of Events Scale; LES = Life Experience
Survey; LSI = Life Satisfaction Index; ISEL = Interpersonal Support Evaluation List; LOT = Life Orientation Test; LOT-R = Life Orientation Test Revised; MFSI =
Multidimensional Fatigue Symptom Inventory; MPQ-SF = Short Form McGill Pain Questionnaire; MUIS-C = Mishel Uncertainty in Illness Scale-Community; OARS =
Older American Services and Resources Questionnaire; PANAS = Positive and Negative Affect Scale; PCL-C = Posttraumatic Stress Disorder Checklist-Civilian;
POMS = Profile of Mood States; QLACS = Quality of Life in Adult Cancer Survivor Scale; QLI-CV = Quality of Life Index-Cancer Version; QOL-CS = Quality of Life-
Cancer Survivor SF-36 = Medical Outcomes Study 36-item Short Form Health Survey; SDS = Symptom Distress Scale; SPS = Spiritual Perspective Scale; SSQ =
Social Support Questionnaire; STAI = State-Trait Anxiety Inventory
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major physical problems were fatigue, pain, overall phy-
sical health, and menstrual/fertility problems, while the
social concerns included interference with activities at
home, employment, and financial burden.
Non-pharmacological intervention and QoL
Two studies evaluated the effect of non-pharmacological
intervention on QoL among long-term BCS [41,46].
Dirksen et al. [41] reported short-term positive changes
in fatigue, trait anxiety, depression, and QoL following
cognitive behavioral therapy (CBT) for insomnia in BCS.
Perkins et al. [46] showed that Physical Activity and
Lymphedema trial (PAL) had beneficial effects on self-
perceptions of appearance, health, physical strength,
sexuality, relationships, and social functioning, as mea-
sured by the Body Image and Relationships Scale.
Discussion
The transition of a patient with breast cancer from
treatment phase to survivorship phase is an important
aspect of cancer continuum. The number of BCS and
the number of survivorship years will increase with
further advancements in breast cancer treatments. How-
ever, these therapies have persistent side-effects and
toxicity which have been shown to negatively impact a
survivor’s QoL [8]. Thus, there is a pressing need to
understand and monitor the prolonged effects of breast
cancer and its treatment so as to capture the concerns
of the survivors and convey the information to clinical
decision-makers who can use it to create patient-cen-
tered solutions.
To date, QoL assessments in cancer survivors and in
BCS in particular, have employed several valid instru-
m e n t st h a ta s s e s sd i f f e r e n tQ o Ld i m e n s i o n s .A si n d i -
cated by Ferrell and colleagues, consideration of
psychological, social, physical, and spiritual aspects of
QoL is essential in understanding the long-term impact
of breast cancer diagnosis and treatments. Furthermore,
few instruments are available that specifically evaluate
all the different aspects of QoL in BCS. Three cancer-
specific instruments, QLACS, QLI-CV, and QOL-CS
evaluate all four domains of QoL and include questions
specifically relevant to BCS. The EORTC and FACT
instruments are important for measuring cancer-specific
concerns, but they lack some survivor-specific concerns
such as fear of recurrence, compromise with physical
problems, and psychosocial issues. These cancer-specific
instruments have shown similar results related to survi-
vor’s QoL when used in different studies focusing on
BCS. For instance, presence of physical problems such
as fatigue, pain, and insomnia as well psychosocial pro-
blems such as anxiety, depression, and concerns about
appearance were consistently measured by these
instruments.
Another important criterion for the selection of QoL
instruments is to ensure that the instruments have good
psychometric properties. Almost all the instruments in
BCS have reported good psychometric properties such
as reliability and validity. However, most of the instru-
ments have not been tested for responsiveness, an
important property for assessing the change in QoL
over time. The concerns related to different aspects of
QoL change as a survivor transitions to another year of
survivorship. The change may be positive or negative
based on the survivor’s perceptions, expectations, and
overall health. It is, thus, important for the instruments
to capture the changes in patient outcomes that vary
with time. Additionally, none of the generic measures
have been validated in a breast cancer population, creat-
ing a need for validation of these measures for evaluat-
ing changes in self-reported general health status of
patients with cancer as they transition from treatment
phase to survivorship. The generic instruments provide
insight into the complete spectrum of disease and are
useful not only in comparing QoL changes across differ-
ent populations (for example, patients undergoing breast
cancer treatment, patients with metastatic breast cancer,
and breast cancer survivors) but also across different
diseases (for example, comparing BCS with ovarian or
cervical cancer survivors). There are certain domains of
QoL that are more prominent in BCS. For instance, fati-
gue, pain, insomnia, depression, anxiety, and fear of
recurrence are persistent concerns that affect survivors
and these conditions could affect their activities of daily
living, coping skills, and social and role functions. The
review identified only two condition-specific instruments
(FSI and MFSI, measuring fatigue) that have been vali-
dated in BCS. However, these instruments do not fully
assess the concerns of the survivors resulting in a need
for validating the existing condition-specific instruments.
A l s o ,t h e r ea r es o m ed i s e a s e - s p e c i f i ci n s t r u m e n t ss u c h
as Breast Cancer Prevention Trial (BCPT) Symptoms
Scale [47], Impact of Cancer Scale (IOCv2) [48], and
Long-term Quality of Life (LTQL) [49] which have been
validated in BCS population; however, we were unable
to locate studies utilizing these instruments in BCS that
met our inclusion criteria. Overall, QLACS demon-
strated good reliability, validity, and responsiveness in
long-term BCS compared to other instruments that
were reviewed.
Another goal of this review was to evaluate the studies
that assessed QoL in long-term BCS using validated
instruments. These studies assessed inter-connectedness
and the important aspects of Ferrell’sQ o Ld o m a i n s .
Most of the studies showed that these domains are
inter-related. The physical concerns such as sexuality
and menopausal symptoms impact both psychological
and social aspects of QoL. The social concerns including
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negatively impact psychological well-being. The spiritual
well-being helps in improving physical, psychological,
and social well-being by providing strength to cope with
negative effects of breast cancer and its treatment.
The studies also evaluateds p e c i f i cc o n c e r n so fB C S
related to each domain. First, the physical domain of
QoL was most commonly evaluated by the studies, with
most frequent issues being fatigue, sleep problems, and
pain. Additionally, lymphedema (swelling of arms) was
reported only in women treated with breast cancer sur-
gery. These physical problems are typical for breast can-
cer treatment and have long-lasting effects; becoming
even more problematic with increase in age. Second, the
psychological well-being was also most frequently evalu-
ated, with major symptoms being emotional distress and
depression resulting from concerns such as fear of
recurrence, uncertainty, family distress, financial burden,
and worries about appearance. Higher level of psycholo-
gical distress was reported in Hispanic women. Third,
the social well-being was affected by absence of suffi-
cient social support. This was a major concern in
women 50 years and older as well as in Hispanic
women. Fourth, spiritual well-being is also an important
aspect of QoL, but is least often reported by the studies.
Spiritual well-being was evaluated by two studies, one
reported post-treatment positive change in life, while
other study reported good overall QoL in African-Amer-
ican BCS resulting from higher levels of spirituality.
In addition, these studies assessed specific concerns of
BCS related to different demographic and medical vari-
ables. The studies reported an overall improvement in
QoL in BCS, but the findings varied considerably based
on the demographic and medical variables. For instance,
the BCS diagnosed at a younger age experience pro-
blems with social well-being compared to the BCS diag-
nosed at an older age experiencing problems with
physical well-being. The Hispanic women experience a
higher degree of uncertainty compared to women of
other ethnic groups. Moreover, the survivor’s concerns
vary with type of breast cancer treatment. Presence of
lymphedema is common for BCS treated with mastect-
omy and concerns such as fatigue and pain are common
for BCS treated with chemotherapy. Thus, the knowl-
edge of variability in survivor’s concerns is important for
clinicians and decision-makers to help guide proper fol-
low-up care after completion of breast cancer treatment.
Most of the studies have focused on QoL during
breast cancer diagnosis and treatment, but there is a gap
in the literature for studies focusing on long-term BCS.
There is a need for studies comparing and evaluating
the effects of different breast cancer therapies (surgical
treatment, systemic therapies-chemotherapy, hormone
therapy, radiation therapy, newer targeted therapies with
monoclonal antibodies, and adjuvant endocrine therapy)
in long-term BCS. More studies are required comparing
QoL in BCS diagnosed at different stages of breast can-
cer as the extent of treatment and its effects might vary
at different stages of cancer. There is a need for studies
assessing impact of co-morbid conditions in older (> 60
years) BCS. Moreover, the studies analyzing the pro-
blems resulting from cancer recurrence are important.
The studies reported in this review are cross-sectional
studies, thus do not provide change in QoL over time in
BCS. These studies provide varied results in different
groups of BCS, which makes it difficult to generalize
these results to the general population of BCS. Most of
the studies included in this review have used more than
one instrument, in which one or two instruments have
been validated in the breast cancer population; other
instruments used have only been validated in general
population. The spiritual outcomes are the least
reported, and consideration of the spiritual domain in
future studies is important.
Conclusions
This review highlights the significant and persistent
effects of breast cancer and its treatment on long-term
BCS and the inter-connectedness of the psychological,
social, physical, and spiritual aspects of QoL in BCS.
Thus, clinicians and decision-makers need to under-
stand the complexity of problems in long-term BCS to
help guide proper follow-up care after the completion of
breast cancer treatment. This review also provides useful
insight into the unique concerns and needs of BCS,
which can help researchers and clinicians select the
most appropriate instruments to assess the changes in
QoL. The use of validated instruments will not only
provide valid data but also help improve the quality of
care in long-term BCS.
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